Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23121345 | 1.00 | AGTR2 (0.46) | AGTR2CYP3A4 | |
| SCHEMBL25248505 | 0.89 | AGTR2 (0.51) | AGTR2CYP3A4 | |
| SCHEMBL29437911 | 0.89 | AGTR2 (0.51) | AGTR2CYP3A4 | |
| SCHEMBL29047266 | 0.89 | AGTR2 (0.47) | AGTR2CYP3A4 | |
| SCHEMBL29437919 | 0.88 | AGTR2 (0.45) | AGTR2CYP3A4 | |
| SCHEMBL25292058 | 0.88 | AGTR2 (0.45) | AGTR2CYP3A4 | |
| SCHEMBL25248583 | 0.88 | AGTR2 (0.55) | AGTR2CYP3A4 | |
| SCHEMBL25254599 | 0.88 | AGTR2 (0.48) | AGTR2CYP3A4 | |
| SCHEMBL30195104 | 0.88 | AGTR2 (0.54) | AGTR2 | |
| SCHEMBL30645006 | 0.87 | AGTR2 (0.44) | AGTR2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4313976-A1 | SELECTIVE ANGIOTENSIN II RECEPTOR LIGANDS | Vicore Pharma AB (SE) | 2024-02-07 | — | — | EP | disclosed |
| CN-116568682-A | Novel compounds for the treatment of angiotensin II related diseases | 维科尔药物公司 | 2023-08-08 | — | — | CN | disclosed |
| EP-4208460-A1 | NOVEL COMPOUNDS FOR USE IN THE TREATMENT OF DISEASES ASSOCIATED WITH ANGIOTENSIN II | Vicore Pharma AB (SE) | 2023-07-12 | — | — | EP | disclosed |
| WO-2022200786-A1 | SELECTIVE ANGIOTENSIN II RECEPTOR LIGANDS | VICORE PHARMA AB (SE) | 2022-09-29 | — | — | WO | disclosed |
| EP-4031240-A1 | NEW COMPOUNDS | Vicore Pharma AB (SE) | 2022-07-27 | — | — | EP | disclosed |
| WO-2022049372-A1 | NOVEL COMPOUNDS FOR USE IN THE TREATMENT OF DISEASES ASSOCIATED WITH ANGIOTENSIN II | VICORE PHARMA AB (SE) | 2022-03-10 | — | — | WO | disclosed |